28 June 2019 - EMA’s CHMP has recommended granting an extension of indication to Victoza (liraglutide) to include the treatment of children and adolescents aged 10 years or older with type 2 diabetes. 

This medicine is already approved for use together with diet and exercise in adults with type 2 diabetes, on its own or as an add-on to other diabetes medicines.

The efficacy and safety of Victoza in children and adolescents was investigated in a placebo-controlled trial with 134 patients with type 2 diabetes aged 10 – 17 years.

Read EMA press release